Evaluation of <i>Tigecycline</i> Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)

Zemrani Yassin; Ahroui Yassine; Ait Zirri Khadija; Eddyb Saadia; Soraa Nabila

doi:doi:10.11648/j.ajlm.20190402.14

| Peer-Reviewed

Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)

Zemrani Yassin, Ahroui Yassine, Ait Zirri Khadija, Eddyb Saadia, Soraa Nabila

Published in American Journal of Laboratory Medicine (Volume 4, Issue 2)

Received: 16 March 2019 Accepted: 16 April 2019 Published: 17 May 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.

Published in	American Journal of Laboratory Medicine (Volume 4, Issue 2)
DOI	10.11648/j.ajlm.20190402.14
Page(s)	44-47
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Tigecycline, Multidrug-Resistant Bacteria, In Vitro Activity

References

[1]	Ramirez A. Controlling multiple-drug-resistant organisms at the hospital level. Expert Opin Pharmacother 2006; 7: 1449–55.
[2]	Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges. J Hosp Infect 2003; 55 (Suppl 1): 1–12.
[3]	Stein GE, Babinchak T. Tigecycline: an update. Diagnostic Microbiology and Infectious Disease Volume 75, Issue 4, April 2013, Pages 331-336.
[4]	Pournaras S, Koumaki V, Gennimata V, Kouskouni E, Tsakris A. In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms. Adv Exp Med Biol. 2016; 897: 1-14.
[5]	Yan Sun, Yun Cai, Xu Liu, Nan Bai, Beibei Liang, Rui Wang. The emergence of clinical resistance to tigecycline. International Journal of Antimicrobial Agents 41 (2013): 110–116.
[6]	C. Bris, G. Auger, F. Kowalczyk, M. Eveillard, M.-L. Joly-Guillou, M. Kempf. Activité in vitro de la Tigécycline vis-à-vis de 760 souches bactériennes isolées au CHU d’Angers–le programme TEST 2006–2009 pathologie Biologie 60 (2012): 336–339.
[7]	Y. Rio, P. Okamba, A. Staal, J. Didion, F. Jurin. Activité in vitro de la Tigécycline vis-à-vis des germes pathogènes isolés d’infections respiratoires en Europe. Le programme TEST 2004–2007. Pathol Biol 2009; 57: 13–6.
[8]	Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008 Nov; 62 (5): 895-904.
[9]	Kempf M, Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2011.
[10]	Park GE, Kang CI, Cha MK, Cho SY, Seok H, Lee JH, Kim JY, Ha YE, Chung DR, Peck KR, Lee NY, Song JH. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors. Int J Infect Dis. 2017 Sep; 62: 26-31.
[11]	Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009; 63: 775–80.
[12]	Yee-Huang Ku. Chi-Chung Chen. Mei-Feng Lee. Yin-Ching Chuang. Hung-Jen Tang. Wen-Liang Yu. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance. Journal of Microbiology, Immunology and Infection Volume 50, Issue 6, December 2017, Pages 931-939.
[13]	Li J, Yang X, Chen L, Duan X, Jiang Z. In Vitro Activity of Various Antibiotics in Combination with Tigecycline Against Acinetobacter baumannii: A Systematic Review and Meta-Analysis. Microb Drug Resist. 2017 Dec; 23 (8): 982-993.

Cite This Article

Plain Text BibTeX RIS

APA Style

Zemrani Yassin, Ahroui Yassine, Ait Zirri Khadija, Eddyb Saadia, Soraa Nabila. (2019). Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). American Journal of Laboratory Medicine, 4(2), 44-47. https://doi.org/10.11648/j.ajlm.20190402.14

Copy | Download

ACS Style

Zemrani Yassin; Ahroui Yassine; Ait Zirri Khadija; Eddyb Saadia; Soraa Nabila. Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). Am. J. Lab. Med. 2019, 4(2), 44-47. doi: 10.11648/j.ajlm.20190402.14

Copy | Download

AMA Style

Zemrani Yassin, Ahroui Yassine, Ait Zirri Khadija, Eddyb Saadia, Soraa Nabila. Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). Am J Lab Med. 2019;4(2):44-47. doi: 10.11648/j.ajlm.20190402.14

Copy | Download

@article{10.11648/j.ajlm.20190402.14,
  author = {Zemrani Yassin and Ahroui Yassine and Ait Zirri Khadija and Eddyb Saadia and Soraa Nabila},
  title = {Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)},
  journal = {American Journal of Laboratory Medicine},
  volume = {4},
  number = {2},
  pages = {44-47},
  doi = {10.11648/j.ajlm.20190402.14},
  url = {https://doi.org/10.11648/j.ajlm.20190402.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190402.14},
  abstract = {The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)
AU  - Zemrani Yassin
AU  - Ahroui Yassine
AU  - Ait Zirri Khadija
AU  - Eddyb Saadia
AU  - Soraa Nabila
Y1  - 2019/05/17
PY  - 2019
N1  - https://doi.org/10.11648/j.ajlm.20190402.14
DO  - 10.11648/j.ajlm.20190402.14
T2  - American Journal of Laboratory Medicine
JF  - American Journal of Laboratory Medicine
JO  - American Journal of Laboratory Medicine
SP  - 44
EP  - 47
PB  - Science Publishing Group
SN  - 2575-386X
UR  - https://doi.org/10.11648/j.ajlm.20190402.14
AB  - The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.
VL  - 4
IS  - 2
ER  -

Copy | Download

Author Information

Zemrani Yassin

Laboratory of Medical Analysis, Microbiology Unit, University Hospital and Faculty of Medicine and Pharmacy, Cadi Ayad University, Marrakech, Morocco
Ahroui Yassine

Laboratory of Medical Analysis, Microbiology Unit, University Hospital and Faculty of Medicine and Pharmacy, Cadi Ayad University, Marrakech, Morocco
Ait Zirri Khadija

Laboratory of Medical Analysis, Microbiology Unit, University Hospital and Faculty of Medicine and Pharmacy, Cadi Ayad University, Marrakech, Morocco
Eddyb Saadia

Laboratory of Medical Analysis, Microbiology Unit, University Hospital and Faculty of Medicine and Pharmacy, Cadi Ayad University, Marrakech, Morocco
Soraa Nabila

Laboratory of Medical Analysis, Microbiology Unit, University Hospital and Faculty of Medicine and Pharmacy, Cadi Ayad University, Marrakech, Morocco

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Zemrani Yassin, Ahroui Yassine, Ait Zirri Khadija, Eddyb Saadia, Soraa Nabila. (2019). Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). American Journal of Laboratory Medicine, 4(2), 44-47. https://doi.org/10.11648/j.ajlm.20190402.14

Copy | Download

ACS Style

Zemrani Yassin; Ahroui Yassine; Ait Zirri Khadija; Eddyb Saadia; Soraa Nabila. Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). Am. J. Lab. Med. 2019, 4(2), 44-47. doi: 10.11648/j.ajlm.20190402.14

Copy | Download

AMA Style

Zemrani Yassin, Ahroui Yassine, Ait Zirri Khadija, Eddyb Saadia, Soraa Nabila. Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco). Am J Lab Med. 2019;4(2):44-47. doi: 10.11648/j.ajlm.20190402.14

Copy | Download

@article{10.11648/j.ajlm.20190402.14,
  author = {Zemrani Yassin and Ahroui Yassine and Ait Zirri Khadija and Eddyb Saadia and Soraa Nabila},
  title = {Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)},
  journal = {American Journal of Laboratory Medicine},
  volume = {4},
  number = {2},
  pages = {44-47},
  doi = {10.11648/j.ajlm.20190402.14},
  url = {https://doi.org/10.11648/j.ajlm.20190402.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190402.14},
  abstract = {The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Tigecycline Susceptibility in Multidrug-Resistant Bacteria at the University Hospital of Marrakech (Morocco)
AU  - Zemrani Yassin
AU  - Ahroui Yassine
AU  - Ait Zirri Khadija
AU  - Eddyb Saadia
AU  - Soraa Nabila
Y1  - 2019/05/17
PY  - 2019
N1  - https://doi.org/10.11648/j.ajlm.20190402.14
DO  - 10.11648/j.ajlm.20190402.14
T2  - American Journal of Laboratory Medicine
JF  - American Journal of Laboratory Medicine
JO  - American Journal of Laboratory Medicine
SP  - 44
EP  - 47
PB  - Science Publishing Group
SN  - 2575-386X
UR  - https://doi.org/10.11648/j.ajlm.20190402.14
AB  - The phenomenon of bacterial resistance to antibiotics is a major public health problem. The prevalence of multidrug-resistant bacteria is rapidly increasing with heavy consequences in terms of morbidity and mortality and health care costs. Tigecycline is a new active glycylcycline on this type of germ and could be a therapeutic alternative for the management of these infections. The aim of this work is to evaluate the in vitro activity of Tigecycline against multidrug-resistant organisms isolated at Mohammed VI hospital in Marrakech. It is a descriptive prospective study of a series of 171 multidrug-resistant bacteria including 102 clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) and 85 clinical isolates of multidrug-resistant Acinetobacter baumannii. The in vitro activity of Tigecycline was measured by the determination of the minimum inhibitory concentration (MIC) by diffusion method on agar medium using the strips "E-test" according to the recommendations of the CASFM. 71% of Acinetobacter baumannii isolates were sensitive to Tigecycline of with MIC ≤1mg / l, while 17.6% of tested strains had intermediate sensitivity to Tigecycline with a MIC between 1 and 2 mg / l, 11,4% were resistant with a MIC> 2 mg / l. ESBL enterobacterial strains were mostly (77,5%) with a MIC ≤ 1 mg / l. Intermediate sensitivity was found in 15.6% of the isolates with a MIC between 1 and 2 mg / l, however, resistance to Tigecycline was found in 6.8% of enterobacterial isolates with a MIC> 2 mg /l. Tigecycline is an interesting therapeutic option and may have an important role in the treatment of multidrug-resistant infections. Detection of the sensitivity status of Tigecycline is necessary to optimize its use and preserve this molecule in our therapeutic arsenal.
VL  - 4
IS  - 2
ER  -

Copy | Download